Sanofi Consumer Healthcare India Ltd Q4 FY25 Results
SANOFICONRQ4 FY25 ResultsAnnounced 2 May 2025, 08:13 pm| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 172.60 | 76.2% |
| Total Income | 177.80 | 75.9% |
| Expenditure | 111.00 | 76.0% |
| PBT | 66.80 | 72.9% |
| Net Profit | 50.00 | 72.4% |
| OPM | 37.08% | 5.97pp |
| NPM | 28.12% | 3.58pp |
| EPS | 21.69 | 72.4% |
Sanofi Consumer Healthcare India Ltd. Q1 results: PAT up 12.9%, EPS at 21.7, Revenue from operations at 1726 million
02 May 2025 · 2 May 2025, 11:59 pm
Summary
Sanofi Consumer Healthcare India Ltd. announced its Q1 results with a 12.9% increase in PAT from the last quarter of Q4 2024. The EPS stands at 21.7 with an increase of 2.4 per share. The company reported revenue from operations of 1726 million. The Q1 2025 also witnessed a successful launch of Allegra D. The Q1 2025 and Q1 2024 are not directly comparable due to demerger and product recall.
Key Highlights
- 1
PAT up by 12.9% in Q1 2025 compared to Q4 2024
- 2
EPS increased by 2.4 per share, landing at 21.7
- 3
Revenue from operations reported at 1726 million
- 4
Successful launch of Allegra D in Q1 2025
- 5
Q1 2025 and Q1 2024 not directly comparable due to demerger and product recall
Management Comments
Himanshu Bakshi
We continue to focus on strengthening our operations and continue to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy.
Informational and educational content only. Not investment advice.